120 related articles for article (PubMed ID: 19671754)
1. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death.
Pritchard JR; Cosgrove BD; Hemann MT; Griffith LG; Wands JR; Lauffenburger DA
Mol Cancer Ther; 2009 Aug; 8(8):2183-92. PubMed ID: 19671754
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Park MA; Zhang G; Mitchell C; Rahmani M; Hamed H; Hagan MP; Yacoub A; Curiel DT; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2008 Sep; 7(9):2633-48. PubMed ID: 18790746
[TBL] [Abstract][Full Text] [Related]
3. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.
Mitchell C; Park MA; Zhang G; Han SI; Harada H; Franklin RA; Yacoub A; Li PL; Hylemon PB; Grant S; Dent P
Mol Cancer Ther; 2007 Feb; 6(2):618-32. PubMed ID: 17308059
[TBL] [Abstract][Full Text] [Related]
4. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
[TBL] [Abstract][Full Text] [Related]
5. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
8. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
9. Combination of HSP90 and autophagy inhibitors promotes hepatocellular carcinoma apoptosis following incomplete thermal ablation.
Chen F; Xie H; Bao H; Violetta L; Zheng S
Mol Med Rep; 2020 Jul; 22(1):337-343. PubMed ID: 32319654
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
11. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition.
Huang Z; Zhou X; He Y; Ke X; Wen Y; Zou F; Chen X
Sci Rep; 2016 Dec; 6():38072. PubMed ID: 27909289
[TBL] [Abstract][Full Text] [Related]
13. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
14. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
15. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
[TBL] [Abstract][Full Text] [Related]
16. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
17. [Influence of 17AAG on proliferation and invasion of gastric cancer cell and its mechanism].
Cui Y; Yu Y; Liu T; Xie Q; Wu W; Liu K
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Oct; 17(10):1031-5. PubMed ID: 25341914
[TBL] [Abstract][Full Text] [Related]
18. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R
Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
Enmon R; Yang WH; Ballangrud AM; Solit DB; Heller G; Rosen N; Scher HI; Sgouros G
Cancer Res; 2003 Dec; 63(23):8393-9. PubMed ID: 14679001
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue.
Pataer A; Bocangel D; Chada S; Roth JA; Hunt KK; Swisher SG
Cancer Gene Ther; 2007 Jan; 14(1):12-8. PubMed ID: 17024233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
